Democratizing hedge fund level analysis tools for everyone
| Name | Indofarma Tbk. |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Health Care Research |
| Code | F2 |
| Latest Quarterly | 06-30-25 |
| Name | Latest % | A Month Ago % |
|---|---|---|
| PT. Bio Farma (Persero) | 80.66 | 80.66 |
| Public < 5% | 11.99 | 11.99 |
| PT. Asabri (Persero) - Dapen Tni | 7.34 | 7.34 |
| Source | 2022 | 2021 |
|---|---|---|
| INAF | F2 | Medicine |
| INAF | F2 | Medical Devices & Others |
| INAF | F2 | Others |
| INAF | F2 | Engineering Pharmaceutical |
| Region | 2022 | 2021 |
|---|---|---|
| INAF | F2 | Indonesia |
| INAF | F2 | Others |
| Valuation | Ratio | Rank |
|---|---|---|
| P/S | 2.91 | # 14 / 15 |
| EV_EBITDA | -24.13 | --- / 15 |
| PER | -4.48 | --- / 15 |
| PBV | -0.47 | --- / 15 |
| DER | -1.69 | --- / 15 |
| Profitability | Ratio | Rank |
|---|---|---|
| NPM % | -64.9709 | --- / 15 |
| ROA % | -15.55999999999999 | --- / 15 |
| ROE % | 10.5 | # 10 / 15 |
| Year | DPS | Yield [%] |
|---|
| Timeframe | Performance |
|---|---|
| 1W % | -3.1 |
| 1Mo % | -45.2 |
| 3Mo % | -68.8 |
| 1Yr % | -79.7 |
| Stocks | PER | Market Cap | EV | Revenue | EBITDA | Net Profit |
|---|---|---|---|---|---|---|
| KLBF | 15.76 | 62.26 T | 63.77 T | 34,159 B | 5,862 B | 3,950 B |
| SOHO | 44.61 | 25.89 T | 28.01 T | 10,338 B | 711 B | 581 B |
| SIDO | 14.24 | 17.10 T | 16.78 T | 3,657 B | 1,604 B | 1,201 B |
| TSPC | 8.97 | 12.63 T | 11.54 T | 13,197 B | 1,807 B | 1,404 B |
| PYFA | -13.79 | 5.90 T | 11.63 T | 2,771 B | -27 B | -426 B |
| KAEF | -8.56 | 3.48 T | 14.83 T | 8,673 B | 365 B | -409 B |